Floxuridine (FUDR)
Other Medications · Approved since 1970
Description
Floxuridine (FUDR) is a fluoropyrimidine antimetabolite chemotherapy agent used primarily for regional therapy in colorectal cancer patients with liver metastases. It is most commonly administered via hepatic arterial infusion (HAI) to deliver high concentrations of chemotherapy directly to liver tumors while minimizing systemic toxicity. The drug is also utilized in hyperthermic intraperitoneal chemotherapy (HIPEC) protocols for patients with peritoneal metastases from colorectal cancer.
Mechanism of Action
Floxuridine is converted intracellularly to 5-fluorouracil and then to active metabolites that inhibit thymidylate synthase, a key enzyme required for DNA synthesis. This inhibition depletes thymidine triphosphate pools and incorporates fraudulent nucleotides into DNA, ultimately leading to cell cycle arrest and apoptosis in rapidly dividing cancer cells.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | FUDR |
| Category | Other Medications |
 Status | FDA Approved |
 EMA Status | Not submitted to EMA |
 Spain Access | Not funded |
| Administration | IV |
| Year Approved | 1970 |
| Clinical Trials | 2 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.